19 Sep 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Clinical research firm, Pharmaceutical Product Development (PPD), has appointed Mr Gregory Dennis, as VP of global product development. In this role, Dr Dennis serves as therapeutic area head, providing medical and scientific expertise for rheumatology, immunology and inflammatory diseases.
"Dr Dennis brings extensive product development and commercialization experience and will play a key role in helping clients plan and address critical drug development challenges," said Mr Rob Dow, global head of medical affairs for PPD.
Mr Dow added, "His background with biopharmaceutical companies and government agencies adds value to PPD's global clinical trial experience in a variety of rheumatology, immunology and inflammatory areas, including osteoarthritis, rheumatoid arthritis, gout, lupus and psoriasis."
Deep therapeutic area expertise is integral to PPD's comprehensive service offerings, including integrated laboratory, phase I-IV and consulting services. PPD manages hundreds of clinical studies each year and leverages this expertise and experience to create optimal design decisions, efficient processes and economies of scale for clients.
Dr Dennis comes to PPD from UCB, where he served as head of immunology for US medical affairs and participated extensively in guiding compounds through the regulatory approval process. Previously, he held leadership roles at Human Genome Sciences, MedImmune and the National Institutes of Health. He retired from the US Army Medical Corps as a colonel, chief of rheumatology and consultant to the army surgeon general.